Catabolic mediators of cancer cachexia

Michael J. Tisdale

Research output: Contribution to journalArticle

Abstract

Purpose of review This review compares the catabolic actions of tumour necrosis factor-a (TNF-a) and proteolysis-inducing factor (PIF) and their involvement in human cancer cachexia. Recent findings TNF-a has a direct catabolic effect on skeletal muscle and adipose tissue, whereas PIF only has an effect on skeletal muscle. Both produce muscle atrophy through a depression of protein synthesis and an increase in protein degradation through the ubiquitin-proteasome proteolytic pathway, and this involves formation of reactive oxygen species leading to upregulation of the transcription factor nuclear factor-kκB (NF-kκB). TNF-aα depresses protein synthesis through decreased phosphorylation of eukaryotic initiation factor-4E (eIF4E) binding protein (4E-BP1) leading to increased binding of eIF4E and a reduction in the active eIF4F complex, whereas with PIF depression of protein synthesis is due to an increased phosphorylation of eIF2 on the a-subunit. In general, serum levels of TNF-aα do not correlate with weight loss in cancer patients and attempts to treat cachexia by interfering with TNF-aα production, or action, have not been successful. Most studies show that PIF is detectable in the urine of cachectic cancer patients and its presence is indicative of weight loss. It is best to confirm that the band on Western blotting is PIF using both antibodies to the core peptide and the oligosaccharide chains. Summary These results suggest that blocking the PIF receptor or signalling pathways in skeletal muscle might yield new types of agents for the treatment of cancer cachexia.

LanguageEnglish
Pages256-261
Number of pages6
JournalCurrent Opinion in Supportive and Palliative Care
Volume2
Issue number4
DOIs
Publication statusPublished - 1 Dec 2008

Fingerprint

Cachexia
Proteolysis
Eukaryotic Initiation Factor-4E
Neoplasms
Skeletal Muscle
Weight Loss
Tumor Necrosis Factor-alpha
Phosphorylation
Proteins
Muscular Atrophy
Proteasome Endopeptidase Complex
Ubiquitin
Oligosaccharides
Adipose Tissue
Reactive Oxygen Species
Carrier Proteins
Transcription Factors
Up-Regulation
Western Blotting
Urine

Keywords

  • Detection
  • Muscle atrophy
  • Proteolysis-inducing factor
  • Tumour necrosis factor-aα

Cite this

Tisdale, Michael J. / Catabolic mediators of cancer cachexia. In: Current Opinion in Supportive and Palliative Care. 2008 ; Vol. 2, No. 4. pp. 256-261.
@article{627abf7b5aa4480a8f7061ea1e0d16c8,
title = "Catabolic mediators of cancer cachexia",
abstract = "Purpose of review This review compares the catabolic actions of tumour necrosis factor-a (TNF-a) and proteolysis-inducing factor (PIF) and their involvement in human cancer cachexia. Recent findings TNF-a has a direct catabolic effect on skeletal muscle and adipose tissue, whereas PIF only has an effect on skeletal muscle. Both produce muscle atrophy through a depression of protein synthesis and an increase in protein degradation through the ubiquitin-proteasome proteolytic pathway, and this involves formation of reactive oxygen species leading to upregulation of the transcription factor nuclear factor-kκB (NF-kκB). TNF-aα depresses protein synthesis through decreased phosphorylation of eukaryotic initiation factor-4E (eIF4E) binding protein (4E-BP1) leading to increased binding of eIF4E and a reduction in the active eIF4F complex, whereas with PIF depression of protein synthesis is due to an increased phosphorylation of eIF2 on the a-subunit. In general, serum levels of TNF-aα do not correlate with weight loss in cancer patients and attempts to treat cachexia by interfering with TNF-aα production, or action, have not been successful. Most studies show that PIF is detectable in the urine of cachectic cancer patients and its presence is indicative of weight loss. It is best to confirm that the band on Western blotting is PIF using both antibodies to the core peptide and the oligosaccharide chains. Summary These results suggest that blocking the PIF receptor or signalling pathways in skeletal muscle might yield new types of agents for the treatment of cancer cachexia.",
keywords = "Detection, Muscle atrophy, Proteolysis-inducing factor, Tumour necrosis factor-aα",
author = "Tisdale, {Michael J.}",
year = "2008",
month = "12",
day = "1",
doi = "10.1097/SPC.0b013e328319d7fa",
language = "English",
volume = "2",
pages = "256--261",
journal = "Current Opinion in Supportive and Palliative Care",
issn = "1751-4258",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

Catabolic mediators of cancer cachexia. / Tisdale, Michael J.

In: Current Opinion in Supportive and Palliative Care, Vol. 2, No. 4, 01.12.2008, p. 256-261.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Catabolic mediators of cancer cachexia

AU - Tisdale, Michael J.

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Purpose of review This review compares the catabolic actions of tumour necrosis factor-a (TNF-a) and proteolysis-inducing factor (PIF) and their involvement in human cancer cachexia. Recent findings TNF-a has a direct catabolic effect on skeletal muscle and adipose tissue, whereas PIF only has an effect on skeletal muscle. Both produce muscle atrophy through a depression of protein synthesis and an increase in protein degradation through the ubiquitin-proteasome proteolytic pathway, and this involves formation of reactive oxygen species leading to upregulation of the transcription factor nuclear factor-kκB (NF-kκB). TNF-aα depresses protein synthesis through decreased phosphorylation of eukaryotic initiation factor-4E (eIF4E) binding protein (4E-BP1) leading to increased binding of eIF4E and a reduction in the active eIF4F complex, whereas with PIF depression of protein synthesis is due to an increased phosphorylation of eIF2 on the a-subunit. In general, serum levels of TNF-aα do not correlate with weight loss in cancer patients and attempts to treat cachexia by interfering with TNF-aα production, or action, have not been successful. Most studies show that PIF is detectable in the urine of cachectic cancer patients and its presence is indicative of weight loss. It is best to confirm that the band on Western blotting is PIF using both antibodies to the core peptide and the oligosaccharide chains. Summary These results suggest that blocking the PIF receptor or signalling pathways in skeletal muscle might yield new types of agents for the treatment of cancer cachexia.

AB - Purpose of review This review compares the catabolic actions of tumour necrosis factor-a (TNF-a) and proteolysis-inducing factor (PIF) and their involvement in human cancer cachexia. Recent findings TNF-a has a direct catabolic effect on skeletal muscle and adipose tissue, whereas PIF only has an effect on skeletal muscle. Both produce muscle atrophy through a depression of protein synthesis and an increase in protein degradation through the ubiquitin-proteasome proteolytic pathway, and this involves formation of reactive oxygen species leading to upregulation of the transcription factor nuclear factor-kκB (NF-kκB). TNF-aα depresses protein synthesis through decreased phosphorylation of eukaryotic initiation factor-4E (eIF4E) binding protein (4E-BP1) leading to increased binding of eIF4E and a reduction in the active eIF4F complex, whereas with PIF depression of protein synthesis is due to an increased phosphorylation of eIF2 on the a-subunit. In general, serum levels of TNF-aα do not correlate with weight loss in cancer patients and attempts to treat cachexia by interfering with TNF-aα production, or action, have not been successful. Most studies show that PIF is detectable in the urine of cachectic cancer patients and its presence is indicative of weight loss. It is best to confirm that the band on Western blotting is PIF using both antibodies to the core peptide and the oligosaccharide chains. Summary These results suggest that blocking the PIF receptor or signalling pathways in skeletal muscle might yield new types of agents for the treatment of cancer cachexia.

KW - Detection

KW - Muscle atrophy

KW - Proteolysis-inducing factor

KW - Tumour necrosis factor-aα

UR - http://www.scopus.com/inward/record.url?scp=61749103068&partnerID=8YFLogxK

U2 - 10.1097/SPC.0b013e328319d7fa

DO - 10.1097/SPC.0b013e328319d7fa

M3 - Article

VL - 2

SP - 256

EP - 261

JO - Current Opinion in Supportive and Palliative Care

T2 - Current Opinion in Supportive and Palliative Care

JF - Current Opinion in Supportive and Palliative Care

SN - 1751-4258

IS - 4

ER -